S Ozgur

Summary

Publications

  1. ncbi HLA class I and II antigens expression in patients with renal cell carcinoma
    B Cem Ozgur
    Department of Urology, Turkey Yuksek Ihtisas Education and Training Hospital, Ankara, Turkey
    Saudi J Kidney Dis Transpl 20:97-101. 2009
  2. ncbi The efficacy of an enuresis alarm in monosymptomatic nocturnal enuresis
    B C Ozgür
    Urology Department, Ankara Gazi Hospital, Gazi Mahallesi Silahtar Street, Yenimahalle 06330, Ankara, Turkey
    Singapore Med J 50:879-80. 2009
  3. ncbi Sildenafil or vardenafil nonresponders' erectile response to tadalafil
    Berat Cem Ozgur
    Department of Urology, Ankara Gazi Hospital, Ankara, Turkey
    Urol J 6:267-71. 2009

Collaborators

  • B Cem Ozgur
  • Berat Cem Ozgur
  • Faruk Gonenc
  • Ahmet H Yazicioglu
  • B C Ozgür
  • V Dogan
  • U A Orun

Detail Information

Publications3

  1. ncbi HLA class I and II antigens expression in patients with renal cell carcinoma
    B Cem Ozgur
    Department of Urology, Turkey Yuksek Ihtisas Education and Training Hospital, Ankara, Turkey
    Saudi J Kidney Dis Transpl 20:97-101. 2009
    ..We found a significantly higher frequency of the alleles HLA-A1, HLA-A26 and HLA-DR11in RCC patients compared to the control group. Larger studies are required to confirm these results...
  2. ncbi The efficacy of an enuresis alarm in monosymptomatic nocturnal enuresis
    B C Ozgür
    Urology Department, Ankara Gazi Hospital, Gazi Mahallesi Silahtar Street, Yenimahalle 06330, Ankara, Turkey
    Singapore Med J 50:879-80. 2009
    ..Of the various treatment options, the enuresis alarm has been widely advocated for treating nocturnal enuresis. This study was designed to evaluate the success rates of the enuretic alarm device in patients with MNE...
  3. ncbi Sildenafil or vardenafil nonresponders' erectile response to tadalafil
    Berat Cem Ozgur
    Department of Urology, Ankara Gazi Hospital, Ankara, Turkey
    Urol J 6:267-71. 2009
    ..This study was performed in order to evaluate the efficacy of the lastly presented phosphodiesterase 5 inhibitor, tadalafil, in nonresponder group of patients to sildenafil and vardenafil...